Clinical Trials & Research
Search Clinical Trials
|Title||Study of PX-866 and Docetaxel in Solid Tumors|
|Disease/Condition||Head and Neck Cancer|
|Description||Phase 1: The purpose is to determine the maximally tolerated dose (MTD) or recommended dose (RD) and any potential efficacy of PX-866 in combination with docetaxel in patients with solid tumors.|
Phase 2: The purpose is to determine the antitumor activity and safety of PX-866 in combination with docetaxel versus docetaxel alone in patients with NSCLC or SCCHN.
|Eligibility Criteria||To be eligible for this study, patients must meet several criteria, including but not limited to the following:|
* Patient must be 18 Years and older
* Patient has either locally advanced, recurrent, or metastatic NSCLC for which they have received at least 1 and no more than 2 prior systemic treatment regimens that may include up to 1 platinum based chemotherapy regimen and/or an epidermal growth factor receptor (EGFR) inhibitor OR locally advanced, recurrent or metastatic SCCHN for which they have received at least one and no more than two prior systemic treatment regimens.
* The patient, in the opinion of the clinical investigator, has a life expectancy of more than 3 months.
|Principal Investigator||Missak Haigentz, MD|
|Contact Name||Yoko Eng, NP|
|Current Trial Type||Interventional|